HBI Deals+Insights / News
With France facing persistent medicine shortages and heightened political focus on healthcare sovereignty, the generic pharmaceuticals sector is drawing increased attention from private investors and policymakers alike. Growing interest in maintaining domestic production and securing supply chains has positioned French generics as both a strategic asset and a market opportunity.





